NICE recommends Eli Lilly's psoriatic arthritis drug

Ixekizumab was granted EU marketing authorisation in January 2018. The efficacy and safety of ixekizumab was determined from the findings of two randomized, double-blind, placebo-controlled Phase 3 studies involving 780 patients.

The NICE guidelines state that ixekizumab can be used alone or in combination with methotrexate for treating active psoriatic arthritis in adults.

"Up to 30 per cent of people with psoriasis will also develop psoriatic arthritis, a severe form of inflammatory arthritis that can cause swollen, stiff and painful joints.2  It can reduce physical function and lead to a reduction in quality of life2 so we are pleased that NICE is able to recommend this new treatment option," said Dr. Arash Tahbaz, Senior Medical Director, Eli Lilly and Company, UK and Northern Europe.

--------------------------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.